Realist Pharma is a immunotherapy company developing small molecules which has developed a patented platform technology (ReVax) that targets multiple cancers through active immune strategies. The company is located at JLABS @ Toronto.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Realist Pharma main programs being REAL-1 (a _next gen CAR-TÓ cell therapy) and REAL-2 (NCE cancer vaccines), both of the two platforms allow one to target up to 11 tumor markers (e.g., GD2 and GD3), and in the process induce important therapeutic T-cell mediated immune responses.
In Sep 2017, Realist Pharma signed a contribution agreement with the Canadian Glycomics Network (GlycoNet) to assist in development of Realists glycomimetic vaccines targeting multiple cancers. In the agreement, GlycoNet will provide a $250,000 financial contribution and expertise for the scale-up of manufacturing of key precursors, for the subsequent GMP manufacturing of material for upcoming clinical studies. In turn, GlycoNet will receive an equity stake in Realist Pharma.
In Apr 2016, Realist Pharma raises a seed round with the support of Emerillon Capital, with a view to advancing its immuno-oncology programs and initiating clinical trials.